1
|
Kuroda H, Kinomoto T, Ogawa S, Kawabe M, Suguro M, Naraoka H, Takamatsu K, Oishi Y. Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model. J Toxicol Pathol 2017; 31:35-41. [PMID: 29479138 PMCID: PMC5820101 DOI: 10.1293/tox.2017-0035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 08/23/2017] [Indexed: 11/23/2022] Open
Abstract
Although acotiamide hydrochloride hydrate (acotiamide-HH) has not been reported to have genotoxic findings in any of the genotoxicity studies or treatment-related toxicological findings in reproductive and developmental studies, suspicious uterine tumorigenesis was observed in the results of a long-term rat carcinogenicity study. To clarify the uterine tumorigenesis of acotiamide-HH, we performed a 2-stage uterine carcinogenicity model in the transgenic rasH2 mouse initiated by N-Ethyl-N-nitrosourea (ENU). This model facilitated the short-term detection of uterine carcinogenic potential, and it appears to be a very useful testing method for assessing the safety of chemicals that may affect uterine tumorigenesis. However, there have not been many reports on this model, and accumulation of case studies using this model is recommended to support its usability. In this study, we performed this carcinogenesis model to not only confirm uterine tumorigenesis of acotiamide-HH but also to confirm the reliability of the model. The results of this study revealed that the endometrial adenocarcinoma found in the long-term rat carcinogenicity study possibly arose spontaneously. Also, we confirmed early induction of a uterine tumor as in previous reports and confirmed that 26 weeks is the appropriate treatment period for this rasH2 mouse model according to time-course observations of uterine tumor development.
Collapse
Affiliation(s)
- Hiroyuki Kuroda
- R&D PLANNING, Zeria Pharmaceutical Co., Ltd., 10-11 Nihonbashi Kobuna-cho, Chuo-ku, Tokyo 103-8351, Japan
| | - Toshiko Kinomoto
- Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Aza Numagami, Oshikiri, Kumagaya-shi, Saitama 360-0111, Japan
| | - Shuji Ogawa
- Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Aza Numagami, Oshikiri, Kumagaya-shi, Saitama 360-0111, Japan
| | - Mayumi Kawabe
- DIMS Institute of Medical Science, Inc., 64 Goura, Nishiazai, Azai-cho, Ichinomiya, Aichi 491-0113, Japan
| | - Mayuko Suguro
- DIMS Institute of Medical Science, Inc., 64 Goura, Nishiazai, Azai-cho, Ichinomiya, Aichi 491-0113, Japan
| | - Hitoshi Naraoka
- Tsukuba Research Center, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan
| | - Kazuhiko Takamatsu
- Tsukuba Research Center, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan
| | - Yuji Oishi
- Department Molecular Pathology, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka-City, Osaka 545-8585, Japan
| |
Collapse
|